The Next Generation of Immune Checkpoint Drug Targets

There are also other immune checkpoint targets indentifed besides well-charaterized immune checkpoint targets, promising the next generation of cancer drug targets. These novel immune checkpoint targets are mainly classfied into four families.

LILRA&B family

LILRA &B (leukocyte immunoglobulin like receptor A and B) family is a cluster of protein coding genes. They are related in innate immune system and Class I MHC mediated antigen processing as well as presentation.

Family members:

LILRA&2 family

Leukocyte-associated immunoglobulin-like receptor (LILRA&2) is a cluster of proteins encoded by LILRA&2 genes. The protein family is found to be inhibitory receptores in peripheral mononuclear cells including NK cells, T cells as well as B cells.

Family members:

SLAMF family

Butyrophilins family

Butyrophilins (Btn) is a family of proteins with at least 10 genes in the lg superfamily.

If you are interested in the next generation of immune checkpoint related products, please feel free to contact with us.

References

1. Russell et al. (2018) .Identification and characterisation of the CD40-ligand of Sigmodon hispidus.PLoS ONE 13.
2. Liu, X et al. (2017) .Is CD47 an innate immune checkpoint for tumor evasion?J Hematol Oncol 10.
3. Huang, Y et al. (2017) .Targeting CD47:the achievements and concerns of current studies on cancer immunotherapy.J.Thorac.Dis.9, 168–E174.
4. Mahnke, K.et al (2016) .TIGIT-CD155 Interactions in Melanoma:A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention.J.Invest.Dermatol.136: 9–11.